Impact of HLADQA1*05 and HLADQA1*03 on Safety and Loss of Response to Anti-Tumor Necrosis Factor in Patients With Inflammatory Bowel Disease
HLADQA1*05 is associated with a higher risk of LOR and immunogenicity, particularly to infliximab. HLADQA1*03 seems to play a protective role against LOR, particularly adalimumab. Female sex and infliximab are risk factors for AE.
Authors
- Fernando Gomollón (ORCID: https://orcid.org/0000-0003-0076-3529)
- Julia López de la Cruz (ORCID: https://orcid.org/0000-0002-3193-4936)
- María Concepción Aso Gonzalvo (ORCID: https://orcid.org/0000-0002-9962-6147)
- Juan López‐Pérez (ORCID: https://orcid.org/0000-0003-4164-9300)
- Javier Louro (ORCID: https://orcid.org/0000-0002-2985-3301)
- Carla J. Gargallo-Puyuelo (ORCID: https://orcid.org/0000-0002-3545-2707)
- María Alonso-Colón (ORCID: https://orcid.org/0000-0001-6542-4590)
- Beatriz Gallego Llera
- Samuel J. Martínez‐Domínguez (ORCID: https://orcid.org/0000-0003-0857-8117)
- Sandra G. García (ORCID: https://orcid.org/0000-0002-2670-3922)
Institutions
- Universidad de Zaragoza (ES)
- Karolinska Institutet (SE)
- Centro de Investigación Biomédica en Red (ES)
- Hospital Clínico Universitario Lozano Blesa (ES)
- Instituto de Investigación Sanitaria Aragón (ES)
Publication Details
- Journal
- Journal of Crohn s and Colitis
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1093/ecco-jcc/jjae178
- Citations
- 2
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.10